Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Non-invasive imaging is central to hepatocellular carcinoma (HCC) diagnosis; however, conventional modalities are limited by smaller tumors and other chronic diseases that are often present in patients with HCC, such as cirrhosis. This pilot study evaluated the feasibility of (4S)-4-(3-[F]fluoropropyl)-L-glutamic acid ([F]FSPG) positron emission tomography (PET)/X-ray computed tomography (CT) to image HCC. [F]FSPG PET/CT was compared to standard-of-care (SOC) magnetic resonance imaging (MRI) and CT, and [C]acetate PET/CT, commonly used in this setting. We report the largest cohort of HCC patients imaged to date with [F]FSPG PET/CT and present the first comparison to [C]acetate PET/CT and SOC imaging. This study represents the first in a US HCC population, which is distinguished by different underlying comorbidities than non-US populations.
Procedures: x transporter RNA and protein levels were evaluated in HCC and matched liver samples from The Cancer Genome Atlas (n = 16) and a tissue microarray (n = 83). Eleven HCC patients who underwent prior MRI or CT scans were imaged by [F]FSPG PET/CT, with seven patients also imaged with [C]acetate PET/CT.
Results: x transporter RNA and protein levels were elevated in HCC samples compared to background liver. Over 50 % of low-grade HCCs and ~70 % of high-grade tumors exceeded background liver protein expression. [F]FSPG PET/CT demonstrated a detection rate of 75 %. [F]FSPG PET/CT also identified an HCC devoid of typical MRI enhancement pattern. Patients scanned with [F]FSPG and [C]acetate PET/CT exhibited a 90 and 70 % detection rate, respectively. In dually positive tumors, [F]FSPG accumulation consistently resulted in significantly greater tumor-to-liver background ratios compared with [C]acetate PET/CT.
Conclusions: [F]FSPG PET/CT is a promising modality for HCC imaging, and larger studies are warranted to examine [F]FSPG PET/CT impact on diagnosis and management of HCC. [F]FSPG PET/CT may also be useful for phenotyping HCC tumor metabolism as part of precision cancer medicine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641676 | PMC |
| http://dx.doi.org/10.1007/s11307-016-1007-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical [F]FSPG Positron Emission Tomography Imaging Reveals Heterogeneity in Tumor-Associated System x Activity.
Cancers (Basel)
April 2024
School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
Article Synopsis
- [F]FSPG PET/CT is a promising imaging technique that helps detect cancer by measuring system x transport activity and may also provide insights into glutathione production, a key antioxidant.
- The study analyzed data from patients with head and neck squamous cell cancer (HNSCC) and non-small-cell lung cancer (NSCLC) to compare the distribution and retention of the [F]FSPG radiotracer in tumors and healthy organs.
- Results showed similar patterns of radiotracer retention in healthy organs, with substantial variability in tumor uptake among different cancer types and individual patients, indicating potential differences in cancer biology and treatment implications.
Is System x a Suitable Target for Tumour Detection and Response Assessment with Imaging?
Cancers (Basel)
November 2023
School of Biomedical Engineering and Imaging Sciences, King's College London, St. Thomas' Hospital, London SE1 7EH, UK.
Article Synopsis
- * A review of ten studies utilizing F-FSPG in humans showed mixed results due to varying retention levels in different cancer types and among patients, limiting its use as a diagnostic tool.
- * Despite these challenges, F-FSPG holds promise for assessing early treatment response and predicting treatment resistance, as animal studies suggest it may indicate therapy effectiveness ahead of traditional imaging methods.
Comparative Evaluation of [F]5-Fluoroaminosuberic Acid and (4)-4-3-[F]fluoropropyl)-l-Glutamate as System xC--Targeting Radiopharmaceuticals.
J Nucl Med
August 2023
Life Sciences Division, TRIUMF, Vancouver, British Columbia, Canada;
System [Formula: see text] is an appealing biomarker for targeting oxidative stress with oncologic PET imaging and can serve as an alternative PET biomarker to other metabolic indicators. In this paper, we report a direct comparison of 2 F-labeled amino acid radiopharmaceuticals targeting system [Formula: see text], [F]5-fluoroaminosuberic acid ([F]FASu) and (4)-4-(3-[F]fluoropropyl)-l-glutamate ([F]FSPG), in terms of their uptake specificity and ability to image glioma and lung cancer xenografts in vivo. Both tracers were synthesized according to previously published procedures.
View Article and Find Full Text PDFRadiotracer stereochemistry affects substrate affinity and kinetics for improved imaging of system x in tumors.
Theranostics
April 2022
School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
Amino acid utilization is perturbed in cancer cells, which rewire their metabolism to support cell survival and proliferation. This metabolic reprogramming can be exploited for diagnostic purposes through positron emission tomography imaging of fluorine-18 labeled amino acids. Despite its promise, little is known regarding transporter-recognition of non-natural amino acid stereoisomers or their utility for cancer imaging.
View Article and Find Full Text PDFF-FSPG PET/CT Imaging of System x Transporter Activity in Patients with Primary and Metastatic Brain Tumors.
Radiology
June 2022
From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford Universit
Article Synopsis
- The study involves using a PET tracer called F-FSPG to target a specific transporter overexpressed in tumors, focusing on its effectiveness for detecting brain lesions in cancer patients.
- Twenty-six patients with primary brain tumors or metastases underwent a series of imaging tests, including F-FSPG PET/CT scans, MRIs, and some had FDG PET imaging, to gather comprehensive data on their condition.
- Results showed that F-FSPG PET/CT was effective in identifying all brain lesions and provided valuable insights on lesion differentiation, with relatively high predictive accuracy for outcomes based on specific imaging parameters.